Coherus Oncology (CHRS) Revenue Growth (5y) (2019 - 2026)
Coherus Oncology (CHRS) Revenue Growth (5y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30.41% |
| Mar 31, 2026 | -31.73% |
| Dec 31, 2025 | -35.06% |
| Sep 30, 2025 | -36.67% |
| Jun 30, 2025 | -40.34% |
| Mar 31, 2025 | -42.04% |
| Dec 31, 2024 | -42.58% |
| Sep 30, 2024 | -44.18% |
| Jun 30, 2024 | -34.19% |
| Mar 31, 2024 | -42.62% |
| Jun 30, 2022 | 112.14% |
| Mar 31, 2022 | 226.91% |
| Dec 31, 2021 | 144.24% |
| Sep 30, 2021 | -12.71% |
| Jun 30, 2021 | 44.18% |
| Mar 31, 2021 | 46.37% |
| Dec 31, 2020 | 61.03% |
| Sep 30, 2020 | 73.77% |
| Jun 30, 2020 | 81.62% |
| Mar 31, 2020 | 82.05% |